A few key characteristics of sclerosis should be considered. In the beginning, symptoms are similar to those found in any chronic condition where blood clot formation is abnormal. In the late stages of the disease, the formation of blood clots is not a main problem, though clot formation can persist. Patients will notice the first noticeable symptom in the beginning of their fifties. Although symptoms can be controlled for some time, recovery from the debilitating symptoms of a sclerosis related illness is a rare phenomenon. However, once symptoms have been controlled, patients can often live a normal life.
Arterial stiffness is common both within and among different ethnic groups and can be reduced and/or controlled through pharmacology, exercise and lifestyle modifications. These can benefit the majority of patients with arterial sclerosis.
There is no single cause of scleroderma: there are triggers causing scleroderma to develop, and autoimmune, genetic and hormonal factors that affect scleroderma’s development. Scleroderma can also develop after long periods of not having symptoms, with various other conditions raising the risk for scleroderma, often in combination.\n
sclerosis is an age-related disorder that leads to loss of joint function, joint space narrowing, decreased range of movement, osteoarthritis, and osteoporosis. Sclerosis is more common in females and presents most commonly with knee osteoarthritis with increased pain. This disease does not always lead to deformity and amputations. Sclerosis patients may be symptomatic, but will have no deformity and will not require surgery.
The current therapies to treat sclerosis including steroids in steroid-responsive SSc and intravenous immune globulin in SSc have been proven satisfactory and have not been replaced by any other treatments.
There are multiple diseases that cause sclerosis: they are not the primary cause of this disease. The primary cause is unknown but likely involves genetics, the environment, inflammation and viral infections.
There was a significant reduction in blood flow to the affected area after 10-minutes of treatment. This decrease was related to a significant decrease in heart rate and oxygen saturation as well as an increase in blood flow velocity in the area. Patients also reported that they found the exercise painful. Although blood flow restriction is a very new treatment for heart disease, further prospective research and trials are needed to establish its use as a cardiovascular medicine.
The application of BF is not a useful tool for peripheral artery remodelling. Although it has been demonstrated that BF is able to reduce vascular remodelling, blood flow redistribution could be an alternative mechanism. Although this has not been studied directly, it could explain the inconsistent results that have been obtained with BF application to the extremities.
Scler sclerosis is the most common presentation of chronic liver disease. Although the liver is affected in over 75% of patients with scleroderma and only 15% of patients with [primary biliary cirrhosis](https://www.withpower.com/clinical-trials/primary-biliary-cirrhosis) it seems that only a minority of patients will develop liver cirrhosis. There is some evidence that statin use may reduce the risk of developing severe liver problems. Liver transplantation is the standard treatment for those with end stage liver disease. The new class of immunosuppressant drugs has expanded the potential options for patients with scleroderma and have significantly improved patients' functional status.
These data are consistent with the hypothesis that decreased tissue oxygenation and metabolic fluxes from blood to tissues plays a role in the treatment of various musculoskeletal conditions. These observations are in agreement with previous animal and human data and warrant further evaluation of blood flow restriction as the new paradigm in the management of musculoskeletal pain.